Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.98 EUR | 0.00% | +3.91% | +70.51% |
05/04 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
28/03 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.07M 54.6M 4.55B | Sales 2025 * | 58.83M 62.91M 5.25B | Capitalization | 68.97M 73.75M 6.15B |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M 89.18M | Net income 2025 * | 3M 3.21M 268M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | 11.27M 12.05M 1B | Net cash position 2025 * | 12M 12.83M 1.07B | EV / Sales 2025 * | 0.97 x |
P/E ratio 2024 * |
69
x | P/E ratio 2025 * |
19.1
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 week | +3.91% | ||
Current month | +30.82% | ||
1 month | +35.25% | ||
3 months | +94.63% | ||
6 months | +124.16% | ||
Current year | +70.51% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 01/22/01 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 01/21/01 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 01/21/01 |
Chairman | 51 | 01/21/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 7.98 | 0.00% | 0 |
25/24/25 | 7.98 | +1.79% | 0 |
24/24/24 | 7.84 | +1.55% | 65 |
23/24/23 | 7.72 | -0.77% | 0 |
22/24/22 | 7.78 | +1.30% | 0 |
Delayed Quote Deutsche Boerse AG, April 27, 2024 at 01:11 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- APPH Stock
- APPH Stock